What Is Selank?

Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analogue of tuftsin, an endogenous tetrapeptide (Thr-Lys-Pro-Arg) that plays a role in immune modulation. Selank extends the tuftsin sequence with a Pro-Gly-Pro tripeptide tail, yielding the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. This structural modification is believed to enhance metabolic stability relative to native tuftsin.

Selank has attracted research interest in the areas of anxiolytic pharmacology, neuropeptide science, and immunomodulation in animal models. It is not approved by Health Canada or any Western regulatory body for human therapeutic use. In Canada, Selank is classified as a research compound and is sold exclusively for in-vitro and laboratory research purposes.

This article provides a scientifically grounded overview of Selank’s chemical profile, research background, and preclinical literature. It does not constitute medical advice, diagnostic guidance, or a therapeutic recommendation of any kind.

Chemical Profile and Structure

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its molecular weight is approximately 751.88 g/mol, and its molecular formula is C₃₃H₅₇N₁₁O₉.

Key Chemical Characteristics

• Type: Synthetic heptapeptide (tuftsin analogue)
• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Molecular Weight: ~751.88 g/mol
• CAS Number: 129954-34-3
• Stability: Greater than native tuftsin due to Pro-Gly-Pro C-terminal extension
• Physical Form: Typically lyophilized white powder for research distribution
• Solubility: Soluble in water and aqueous buffers

Tuftsin, the parent peptide, is a naturally occurring fragment of IgG immunoglobulin with documented immunostimulatory effects in animal research. The Pro-Gly-Pro extension in Selank is thought to confer resistance to peptidase degradation while preserving and potentially amplifying aspects of the parent molecule’s biological activity in preclinical models.

Research Background

Selank was developed in the 1990s as part of Russian research programs exploring synthetic analogues of endogenous neuropeptides and immunopeptides. The core research hypothesis was that stabilized tuftsin analogues could exhibit more sustained activity in biological systems compared to the rapidly degraded native tuftsin molecule.

Research programs examining Selank have explored several overlapping themes:

• Anxiolytic research: Animal models of stress and anxiety-related behaviour have been used to examine Selank’s effects on behavioural endpoints
• Immunomodulation: Building on tuftsin’s known immune-related properties, researchers have examined Selank’s effects on cytokine profiles and immune cell function in animal models
• Nootropic parameters: Cognitive and learning-related behavioural endpoints have been examined in rodent models
• BDNF and neurotrophin signalling: Some preclinical work has explored Selank’s influence on brain-derived neurotrophic factor expression

Selank’s research profile overlaps significantly with that of Semax, another Russian-developed neuropeptide research compound. For a direct comparison, see our Semax vs Selank research comparison.

Mechanisms of Interest in Research

Research into Selank has identified several molecular and neurobiological interactions of scientific interest. These are observations from preclinical research and should not be interpreted as established therapeutic mechanisms in humans.

Gabaergic System Interactions

Preclinical research has examined Selank’s interaction with the GABA-A receptor system in animal models. Some studies have reported anxiolytic-like behavioural effects that appear to involve GABAergic transmission, though the precise receptor-binding mechanisms remain an active area of investigation.

Monoaminergic System Modulation

Animal research has documented changes in serotonin, dopamine, and norepinephrine metabolism in specific brain regions following Selank administration in rodent studies. The significance of these findings for cognitive and mood research models is a subject of ongoing scientific interest.

BDNF Expression

Some preclinical studies have documented increased BDNF mRNA expression in rodent hippocampal tissue following Selank administration. BDNF plays an important role in neuronal plasticity and learning-related processes in animal models, making this line of research of interest to neuroscience investigators.

Immune and Cytokine Modulation

Deriving from its tuftsin lineage, Selank has been examined for effects on cytokine profiles including interleukins and interferon in animal and cell-based research models. This represents an exploratory area of research.

Preclinical Research Overview

The published preclinical literature on Selank spans behavioural neuroscience, immunology, and neuropeptide pharmacology. Key research themes include:

Anxiety and Stress Models

Multiple rodent studies using standard anxiolytic assay paradigms (elevated plus maze, light-dark box, open field) have reported dose-dependent anxiolytic-like behavioural effects in animals administered Selank. These studies serve as hypothesis-generating research for neuropeptide pharmacology but cannot be extrapolated to human anxiety disorders.

Cognitive and Learning Research

Rodent cognitive research has examined effects on spatial memory, associative learning, and attention-related tasks. Published animal data suggest Selank may influence learning-related parameters in specific rodent models, though these findings are preliminary and model-specific.

Immunological Research

Cell-based and in-vivo animal research has examined Selank’s effects on natural killer cell activity, macrophage function, and cytokine secretion profiles. This research is at an early exploratory stage and should not be interpreted as evidence of immunotherapeutic activity.

Neurotrophin Studies

A subset of preclinical studies has focused on Selank’s influence on BDNF, NGF (Nerve Growth Factor), and GDNF (Glial Cell Line-Derived Neurotrophic Factor) expression in rodent central nervous system tissue. These represent interesting findings for basic neuroscience research.

For context on peptide research in Canada, see our overview of research peptides in Canada.

Clinical Research Context

In Russia, Selank has achieved regulatory status as a licensed pharmaceutical for specific indications, including anxiety-related conditions, under Russian regulatory frameworks. This status is specific to Russia and does not reflect approval by Health Canada, the FDA, EMA, or any other major Western regulatory authority.

Western clinical research on Selank remains limited. A small number of published human studies have examined Selank in anxiety-related contexts, but these studies are preliminary, small in scale, and have not met the evidentiary standards required for regulatory approval in Canada or comparable jurisdictions.

Researchers operating in Canada should be aware that Selank’s use in human subjects requires ethics board approval and is subject to applicable Canadian research regulations. For broader compliance context, see our guide to research compound safety and compliance.

Storage and Handling

Maintaining proper storage conditions is essential to preserving the integrity of Selank samples for research use. As a peptide, Selank is susceptible to degradation from heat, moisture, and repeated freeze-thaw cycling.

Recommended Storage Conditions

• Long-term storage: −20°C or below in lyophilized form
• Short-term storage: 2–8°C for periods up to several weeks
• Avoid: Repeated freeze-thaw cycles, humidity, direct light exposure, elevated temperatures
• Container: Sealed, amber vials with minimal headspace

For comprehensive storage and handling protocols for research peptides, see our peptide storage guide and peptide reconstitution guide.

Purity and Testing Standards

Research-grade Selank should meet rigorous purity standards to ensure reliable and reproducible results in laboratory protocols. At TrueCanPeptides, all research compounds are accompanied by Certificates of Analysis from verified testing.

Standard Testing Methods

• HPLC (High-Performance Liquid Chromatography): Confirms purity percentage — research-grade compounds should achieve ≥98% purity
• Mass Spectrometry: Verifies molecular identity and molecular weight consistency with expected values
• Amino Acid Analysis: Confirms correct sequence composition

For information on how to evaluate a Certificate of Analysis, see: what is a CoA and why does it matter?

Related Research Compounds

Researchers studying Selank often examine related neuropeptide compounds for comparative or complementary research purposes:

• Semax: A related Russian-developed neuropeptide with overlapping research areas. Compare in our Semax vs Selank comparison article.
• DSIP: Delta Sleep-Inducing Peptide — another neuropeptide investigated in neurological and sleep-related research.
• Cognitive Research Peptides: Overview of peptides studied in cognitive neuroscience research.
• Sleep Research Peptides: Overview of peptides investigated in sleep-related research contexts.

Frequently Asked Questions

Q: What is Selank?

Selank is a synthetic heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro), developed in Russia. It has been investigated in preclinical research for anxiolytic parameters, cognitive endpoints, immunomodulatory effects, and BDNF expression. It is not approved for human use in Canada.

Q: Is Selank legal in Canada?

Selank is not approved by Health Canada for any therapeutic use. It is classified as a research compound available for in-vitro and laboratory research only. Human use outside an ethics-approved research context is not sanctioned under Canadian regulations.

Q: How does Selank differ from Semax?

Both are Russian-developed synthetic heptapeptides with Pro-Gly-Pro tails, but they differ in parent sequences and research focus. Semax derives from ACTH and is most studied for BDNF and neuroprotective parameters. Selank derives from tuftsin and has additional research interest in anxiolytic and immune modulation parameters. See our Semax vs Selank comparison.

Q: What preclinical research has been conducted on Selank?

Published preclinical research has examined anxiolytic-like behavioural effects in rodent models, cognitive and learning endpoints, BDNF expression in CNS tissue, and immunomodulatory effects. Most research originates from Russian academic institutions and is early-stage preclinical in nature.

Q: What purity should research-grade Selank have?

Research-grade Selank should achieve ≥98% purity by HPLC. A Certificate of Analysis should verify purity, molecular identity, and absence of major contaminants. See our CoA guide for evaluation criteria.

Related Articles

• What Is Semax? Research Overview
• Semax vs Selank: Research Comparison
• Peptides for Cognitive Research
• Research Peptides Explained
• Research Compound Safety and Compliance
• Beginner’s Guide to Peptides

See also: What is Semax?